Fresenius Kabi AG

08/10/2022 | Press release | Distributed by Public on 08/10/2022 04:41

Fresenius Kabi establishes partnership with Fiocruz/Bio-Manguinhos and Bionovis to provide access to adalimumab biosimilar in Brazil

Fresenius Kabi, a healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, announces a partnership with Fiocruz/Bio-Manguinhos and Bionovis for the production and supply of Fresenius Kabi's adalimumab biosimilar, IDACIO®* in Brazil. The product is intended for the treatment of several autoimmune diseases in rheumatic, gastrointestinal and skin diseases, such as rheumatoid arthritis, Crohn's disease, and plaque psoriasis, among others.

IDACIO® (adalimumab) is Fresenius Kabi's first biosimilar to be approved and sold in Brazil. This Productive Development Partnership (PDP) is expected to continue for the next ten years.

"We are enthusiastic about this partnership in Brazil, where we have built a solid history of success for more than 40 years. It is an important and promising milestone for our company and Brazil's patients, who will have access to a high-quality treatment through their public health system," said Hernâni Sério, General Manager of Fresenius Kabi Brazil.

The initiative will supply the Brazilian Ministry of Health and Brazil's public health system with Fresenius Kabi's adalimumab biosimilar and facilitate more patient access to effective and more affordable treatment options for chronic and acute diseases in Brazil. IDACIO® (adalimumab), registered with the Brazilian Health Surveillance Agency (Anvisa) in August 2020, will be available for adult and pediatric indications. The drug will be fully reimbursed by the Brazilian Public Health System (SUS) by the second semester of 2022 on.

Fresenius Kabi will ensure full technology transfer, to Fiocruz/Bio-Manguinhos and Bionovis, thus enabling the production and registration of the drug in Brazil.